XML 63 R45.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer concentration risk | 12 Months Ended
--- | ---
Jan. 03, 2025 | Dec. 29, 2023 | Dec. 30, 2022
Affiliates of Cencora, Inc. (formerly AmerisourceBergen Corporation) | Sales revenue, net |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 18.00% | 17.00% | 18.00%
Affiliates of Cencora, Inc. (formerly AmerisourceBergen Corporation) | Accounts Receivable |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 17.00% | 17.00% |
Affiliates of CVS Health Corporation | Sales revenue, net |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 17.00% | 17.00% | 17.00%
Affiliates of CVS Health Corporation | Accounts Receivable |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 20.00% | 20.00% |
Affiliates of McKesson Corporation | Sales revenue, net |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 16.00% | 17.00% | 17.00%
Affiliates of McKesson Corporation | Accounts Receivable |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 23.00% | 21.00% |
Ipsen Pharma SAS | Sales revenue, net |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 15.00% | 8.00% | 10.00%
Ipsen Pharma SAS | Accounts Receivable |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 18.00% | 19.00% |
Accredo Health, Incorporated | Sales revenue, net |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 11.00% | 12.00% | 10.00%
Affiliates of Optum Specialty Pharmacy | Sales revenue, net |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 9.00% | 10.00% | 10.00%
Cardinal Health, Inc. | Accounts Receivable |  |  |
Concentration Risk [Line Items] |  |  |
Percent of total revenues | 10.00% | 11.00% |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesOfCencoraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_IpsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_MajorCustomersAxis=exel_CardinalHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |